Dossier · Private startup · 0 independent sources
Aidoc
Last updated: Jul 31, 2026
Aidoc is an Israeli clinical AI company whose aiOS platform orchestrates FDA-cleared medical-imaging and care-coordination software across hospital workflows, helping teams prioritize time-sensitive findings and act on them faster.
Visit WebsiteCompany Overview
Aidoc develops clinical AI for hospitals, with aiOS serving as an orchestration and governance layer for medical-image analysis and related workflow automation. The platform uses scan pixels, metadata, and textual patient information to route appropriate studies to algorithms, surface suspected and incidental findings in the patient record, prioritize worklists, and notify relevant care teams. Its portfolio has focused on acute conditions such as intracranial hemorrhage, pulmonary embolism, stroke, pneumothorax, and other findings where delayed recognition can affect treatment. Aidoc also describes CARE as a clinical foundation-model effort intended to extend beyond isolated algorithms, while its care-coordination tools connect imaging signals to multidisciplinary response workflows.
The customer is typically a hospital or health system seeking to scale clinical AI beyond disconnected pilots. Aidoc states that its technology is live in more than 1,600 hospitals and 150+ health systems, with 230+ enterprise deployments and 60 million patients supported annually on its current platform pages. It also reports 17 FDA-cleared clinical solutions, more than 220 clinical studies, and deployments in which partner or health-system algorithms run through aiOS. These are company-reported traction indicators rather than independently audited financial results, but they show a materially established commercialization position. The business remains exposed to long hospital procurement, integration, cybersecurity, clinical-governance, and evidence requirements; enterprise adoption is valuable precisely because it is difficult to replicate, but that same complexity can slow expansion.
Competition spans focused clinical-AI vendors such as Viz.ai and RapidAI, broad imaging-AI providers such as Qure.ai, and incumbent imaging and health-IT ecosystems from GE HealthCare, Philips, and Siemens Healthineers. Aidoc's differentiation is therefore less about claiming that one model is uniquely accurate and more about workflow breadth, deployment experience, governance, analytics, and the ability to run multiple algorithms through one enterprise integration. Its public materials cite alliances with NVIDIA and AWS and customer rollouts across large health systems, but diligence should distinguish product usage and clinical-study counts from durable contracted recurring revenue, realized health-economic savings, and retention.
The defense and national-security relevance is credible but adjacent rather than demonstrated. In military medicine, disaster response, and humanitarian field hospitals, limited specialist capacity, distributed imaging, and high casualty volume create a similar need for rapid triage and escalation. A platform that can prioritize scans and coordinate scarce clinical expertise could improve response speed in those settings, subject to connectivity, hardware, cybersecurity, validation, and deployment constraints. I found no public evidence in the reviewed sources of defense contracts or dedicated battlefield deployments, so the dual-use thesis should be treated as a transferability assessment, not proof of defense revenue. Aidoc's Israeli origin and founders' publicly described intelligence backgrounds may be relevant context, but they do not substitute for customer or program evidence.
Dual-Use Assessment
Aidoc's core capabilities have credible but unproven dual-use potential: image triage, prioritization, and care-team coordination could transfer to military medicine, disaster response, and humanitarian field hospitals with scarce specialist capacity. The transfer is constrained by connectivity, device integration, cybersecurity, and the need for deployment-specific clinical validation. No public defense contract or battlefield deployment was identified, so this is a prospective adjacency rather than demonstrated defense traction.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Aidoc merits a high internal priority signal because it combines a difficult-to-build clinical workflow platform, broad reported deployment, regulatory experience, and a 2026 Series E financing led by Goldman Sachs Alternatives. The case is strongest as enterprise healthcare infrastructure with measurable clinical and operational value; the defense angle is supplementary and not supported by public defense revenue. Key diligence questions are contracted recurring revenue, renewal and expansion rates, validated economic outcomes, model performance across sites and populations, regulatory scope for CARE, and the cost and duration of implementations.
Strategic Value to U.S.-Israel Alliance
Aidoc could be strategically valuable as an enterprise layer for deploying and governing clinical AI where timing, auditability, and coordination matter. Its relevance to resilience and national security comes from the possibility of transferring triage and scarce-expertise coordination to military medicine, disaster response, and other distributed care settings. That value depends on proving operation under degraded connectivity, heterogeneous equipment, adversarial cyber conditions, and non-standard patient populations; current public evidence establishes civilian scale, not those conditions.
Key Technologies
- Deep learning-based medical image analysis and finding prioritization
- Multimodal orchestration using scan pixels, metadata, and clinical text
- Real-time integration with hospital PACS, EHR, and communication workflows
- Clinical AI governance with validation, drift detection, and override tracking
- CARE clinical foundation-model capabilities
- Outcome measurement and triage performance analytics
Use Cases & Applications
- Acute stroke, intracranial hemorrhage, and pulmonary embolism triage
- Pneumothorax and other critical chest-finding notification
- Incidental finding capture and follow-up coordination
- Enterprise radiology worklist prioritization
- Multidisciplinary care-team coordination across hospital service lines
- Deployment and governance of partner or health-system AI algorithms
- Distributed and austere medical operations triage, subject to validation
- Humanitarian and disaster-response casualty management
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 5 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- aidoc.com Public source used for profile verification.
- aidoc.com Public source used for profile verification.
- aidoc.com Public source used for profile verification.
- aidoc.com Public source used for profile verification.
- Official website
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Defense & National Security sector page for market context, related subcategories, and other Israeli companies in this part of the database.